Skip to main content
SpringerLink
Log in
Book cover

Tumor Liquid Biopsies pp 147–160Cite as

Clinical Applications of Circulating Tumor Cells in Breast Cancer

  • Chapter
  • First Online:

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 215))

Abstract

The development of metastatic disease accounts for the vast majority of cancer-related deaths in solid tumor malignancies. Distant metastases primarily develop as a result of tumor cell dissemination through the circulatory system.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Alix-Panabieres C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59:110–118

    Article  CAS  Google Scholar 

  • Bidard FC, Mathiot C, Degeorges A et al (2010) Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 21:1765–1771

    Article  Google Scholar 

  • Bidard FC, Peeters DJ, Fehm T et al (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15:406–414

    Article  Google Scholar 

  • Bidard FC, Michiels S, Mueller V et al (2016) IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. In: Paper presented at: 39th San Antonio breast cancer symposium, Dec 2016, San Antonio, TX

    Google Scholar 

  • Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559–1564

    Article  CAS  Google Scholar 

  • Chu D, Paoletti C, Gersch C et al (2016) ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clin Cancer Res 22:993–999

    Article  CAS  Google Scholar 

  • Coget J, Blanchard F, Lamy A et al (2012) Cytologic and molecular characterizations of CTC detected in patients with metastatic colorectal carcinomas. J Clin Oncol 30:485

    Article  Google Scholar 

  • Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791

    Article  CAS  Google Scholar 

  • Dawson SJ, Rosenfeld N, Caldas C (2013) Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 369:93–94

    Article  CAS  Google Scholar 

  • de Bono JS, Attard G, Adjei A et al (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13:3611–3616

    Article  Google Scholar 

  • De Luca F, Rotunno G, Salvianti F et al (2016) Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget 7:26107

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–84

    Google Scholar 

  • Fehm T, Hoffmann O, Aktas B et al (2009) Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11:R59

    Article  Google Scholar 

  • Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892

    Article  CAS  Google Scholar 

  • Ghebeh H, Mohammed S, Al-Omair A et al (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8:190–198

    Article  CAS  Google Scholar 

  • Giordano A, Egleston BL, Hajage D et al (2013) Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res 19:1596–1602

    Article  CAS  Google Scholar 

  • Hayes DF, Cristofanilli M, Budd GT et al (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:4218–4224

    Article  CAS  Google Scholar 

  • Ignatiadis M, Xenidis N, Perraki M et al (2007) Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25:5194–5202

    Article  Google Scholar 

  • Janni WJ, Rack B, Terstappen LW et al (2016) Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res 22:2583–2593

    Article  CAS  Google Scholar 

  • Kallergi G, Mavroudis D, Georgoulias V et al (2007) Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 13:79–88

    Article  CAS  Google Scholar 

  • Lindstrom LS, Karlsson E, Wilking UM et al (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30:2601–2608

    Article  Google Scholar 

  • Liu MC, Shields PG, Warren RD et al (2009) Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27:5153–5159

    Article  Google Scholar 

  • Lucci A, Hall CS, Lodhi AK et al (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13:688–695

    Article  Google Scholar 

  • Mathew A, Brufsky AM, Davidson NE (2015) Can circulating tumor cells predict resistance in metastatic breast cancer? Clin Cancer Res 21:2421–2423

    Article  CAS  Google Scholar 

  • Mazel M, Jacot W, Pantel K et al (2015) Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 9:1773–1782

    Article  CAS  Google Scholar 

  • Meng S, Tripathy D, Shete S et al (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101:9393–9398

    Article  CAS  Google Scholar 

  • Moja L, Tagliabue L, Balduzzi S et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4:CD006243

    Google Scholar 

  • Nanda R, Chow LQ, Dees EC et al (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34:2460–2467

    Article  CAS  Google Scholar 

  • Nygaard AD, Garm Spindler KL, Pallisgaard N et al (2013) The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer 79:312–317

    Article  Google Scholar 

  • Paoletti C, Hayes DF (2016) Circulating tumor cells. Adv Exp Med Biol 882:235–258

    Article  CAS  Google Scholar 

  • Paoletti C, Smerage J, Hayes DF (2012) Circulating tumor cells as a marker of prognosis. Princip Prac Oncol 1–8

    Google Scholar 

  • Paoletti C, Muniz MC, Thomas DG et al (2015) Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res 21:2487–2498

    Article  Google Scholar 

  • Paoletti C, Regan MM, Liu MC, Marcom PK, Hart LL, Smith II JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, Aung K, Cannell EM, Darga EP, Baratta PJ, Brown ME, McCormack RT, Hayes DF (2016) Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: results of the COMETI Phase 2 trial. In: abstr#P01-01-01 San Antonio breast cancer symposium

    Google Scholar 

  • Payne RE, Yague E, Slade MJ et al (2009) Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10:51–57

    Article  CAS  Google Scholar 

  • Pestrin M, Bessi S, Puglisi F et al (2012) Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 134:283–289

    Article  CAS  Google Scholar 

  • Poruk KE, Blackford AL, Weiss MJ et al (2016) Circulating tumor cells expressing markers of tumor initiating cells predict poor survival and cancer recurrence in patients with pancreatic ductal adenocarcinoma. Clin Cancer Res 2016

    Google Scholar 

  • Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017

    Article  Google Scholar 

  • Rack B, Schindlbeck C, Juckstock J et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106

    Google Scholar 

  • Riethdorf S, Muller V, Zhang L et al (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16:2634–2645

    Article  CAS  Google Scholar 

  • Robinson DR, Wu YM, Vats P et al (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45:1446–1451

    Article  CAS  Google Scholar 

  • Rugo H (2015) Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. San Antonio

    Google Scholar 

  • Scher HI, Heller G, Molina A et al (2011) Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 29:LBA4517

    Article  Google Scholar 

  • Schiavon G, Hrebien S, Garcia-Murillas I et al (2015) Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 7:313ra182

    Google Scholar 

  • Smerage JB, Budd GT, Doyle GV et al (2013) Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol 7:680–692

    Article  CAS  Google Scholar 

  • Smerage JB, Barlow WE, Hortobagyi GN et al (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483–3489

    Article  CAS  Google Scholar 

  • Teutsch SM, Bradley LA, Palomaki GE et al (2009) The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med 11:3–14

    Article  Google Scholar 

  • Van Poznak C, Somerfield MR, Bast RC et al (2015) Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 33:2695–2704

    Article  Google Scholar 

  • Wang LH, Pfister TD, Parchment RE et al (2010) Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 16:1073–1084

    Article  CAS  Google Scholar 

  • Weber JS, Kudchadkar RR, Yu B et al (2013) Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31:4311–4318

    Article  CAS  Google Scholar 

  • Xenidis N, Ignatiadis M, Apostolaki S et al (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27:2177–2184

    Article  CAS  Google Scholar 

  • Zhang L, Riethdorf S, Wu G et al (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18:5701–5710

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Breast Oncology Program of the Comprehensive Cancer Center, University of Michigan Health System, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109-5942, USA

    Erin F. Cobain, Costanza Paoletti, Jeffrey B. Smerage & Daniel F. Hayes

Authors
  1. Erin F. Cobain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Costanza Paoletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey B. Smerage
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel F. Hayes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel F. Hayes .

Editor information

Editors and Affiliations

  1. Cancéropôle Est , Strasbourg, France

    Florence Schaffner

  2. Institut de Cancérologie de Lorraine, CNRS UMR7039 CRAN, Université de Lorraine, Vandoeuvre-lès-Nancy, France

    Jean-Louis Merlin

  3. Department of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Lübeck, Germany

    Nikolas von Bubnoff

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cobain, E.F., Paoletti, C., Smerage, J.B., Hayes, D.F. (2020). Clinical Applications of Circulating Tumor Cells in Breast Cancer. In: Schaffner, F., Merlin, JL., von Bubnoff, N. (eds) Tumor Liquid Biopsies. Recent Results in Cancer Research, vol 215. Springer, Cham. https://doi.org/10.1007/978-3-030-26439-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-26439-0_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-26438-3

  • Online ISBN: 978-3-030-26439-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation